newsfilter
← Interviews
Goldman Sachs17 min

From “The Way Forward" Conference: Dr. Leonard S. Schleifer, Co-Founder, Regeneron Pharmaceuticals

Dr. Leonard S. Schleifer, Marshall

Interview, Fireside Chat

Regeneron, led by CEO Dr. Leonard Schleifer and co-founder George Yancopoulos, accelerated antibody therapy development to five months for Ebola and a new viral threat by utilizing a proprietary mouse platform and a dual-antibody cocktail designed to prevent viral escape mutants. The company targets three distinct patient populations with the goal of reducing viral duration and preventing severe progression, prioritizing high-impact intervention over mass vaccination. This strategy leverages converged wet sciences and rapid sequencing technologies to validate the cocktail's efficacy against variants within hours, with critical clinical data anticipated in late summer.